NASDAQ$ESTA
Establishment Labs Holdings Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported record first-quarter financial results, marked by revenue growth and strategic advancements.
Establishment Labs reported a record first quarter with worldwide revenue of $46.5 million, a 21.0% increase year-over-year. The company launched Mia Femtech™ in Japan and presented encouraging 3-year results from the Motiva® U.S. IDE study. A follow-on share offering was completed, raising gross proceeds of $90.4 million to support future growth initiatives.
- First quarter worldwide revenue reached a record $46.5 million, up 21.0% year-over-year.
- Revenue guidance for 2023 remains between $200 million and $210 million, representing a 24% to 30% increase over 2022.
- The company's cash balance as of March 31, 2023, was $42.8 million, which was later fortified with $90.4 million in gross proceeds from a follow-on share offering.
- Mia Femtech™ was launched in Japan, marking the beginning of its global rollout in breast aesthetics.
Headline financials
Revenue & EPS history
Establishment Labs · Revenue · Quarterly
$46.5M
Forward guidance
Establishment Labs anticipates an eventful period with a strategic partnership with Clinique des Champs Elysées, advancing plans for Motiva in China, and the upcoming operation of the Sulàyöm campus.
Tailwinds
- Strategic partnership with Clinique des Champs Elysées to offer the Mia Femtech experience.
- Advancing plans for the launch of Motiva in China.
- PMA accepted by the U.S. FDA and is under review.
- Sulàyöm campus will begin operation later this year, doubling manufacturing capacity.
- New capabilities in R&D, medical education, and media.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.5%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
56%
18 / 32 earnings
Positive
+22.5%
Q3 2025
Best reaction
-26.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -4.3% | +2.9% | |
| Q4 2025 | -1.9% | +5.0% | -20.1% | |
| Q3 2025 | +22.5% | +37.0% | +43.2% | |
| Q1 2025 | +4.9% | +5.1% | +14.2% | |
| Q4 2024 | +17.9% | +28.1% | +12.1% | |
| Q3 2024 | -5.2% | -13.2% | -10.0% | |
| Q2 2024 | +3.4% | +20.6% | +23.5% | |
| Q1 2024 | +5.4% | +4.2% | -10.8% | |
| Q4 2023 | +15.1% | +19.6% | +28.2% | |
| Q3 2023 | -26.0% | -36.1% | -31.7% | |
| Q2 2023 | -8.4% | -12.0% | -12.2% | |
| Q1 2023 | +1.8% | -1.6% | -1.9% | |
| Q4 2022 | +7.2% | +10.3% | +0.3% | |
| Q3 2022 | -7.7% | +11.1% | +27.1% | |
| Q2 2022 | -3.0% | +1.3% | -0.4% | |
| Q1 2022 | -10.5% | -10.1% | +2.3% | |
| Q4 2021 | +3.3% | +1.6% | +11.5% | |
| Q3 2021 | -10.6% | -14.3% | -15.2% | |
| Q2 2021 | +6.0% | -3.7% | -3.1% | |
| Q1 2021 | -0.6% | -1.8% | +8.9% | |
| Q4 2020 | +0.4% | -6.8% | +9.5% | |
| Q3 2020 | +8.9% | -0.4% | +22.6% | |
| Q2 2020 | +6.2% | +7.3% | +9.3% | |
| Q1 2020 | +2.9% | +0.5% | +15.3% | |
| Q4 2019 | +4.5% | -16.4% | +0.4% | |
| Q3 2019 | -0.3% | +0.5% | +7.8% | |
| Q2 2019 | -5.2% | -10.6% | -10.2% | |
| Q1 2019 | +1.5% | -0.3% | -15.9% | |
| Q4 2018 | -1.9% | -4.9% | -15.2% | |
| Q3 2017 | +10.3% | +4.5% | -6.2% | |
| Q3 2018 | +10.3% | +4.5% | -6.2% | |
| Q2 2018 | -2.7% | -2.9% | -3.4% | |
| Q4 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro